Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Research & Development (2016 - 2025)

Lipocine (LPCN) has disclosed Research & Development for 13 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 183.78% year-over-year to $2.1 million, compared with a TTM value of $4.0 million through Sep 2025, up 9.12%, and an annual FY2024 reading of $4.1 million, down 38.81% over the prior year.
  • Research & Development was $2.1 million for Q3 2025 at Lipocine, down from $3.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.1 million in Q2 2025 and bottomed at -$1.8 million in Q4 2023.
  • Average Research & Development over 5 years is $1.3 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 185.76% in 2022, then skyrocketed 183.78% in 2025.
  • Year by year, Research & Development stood at $1.5 million in 2021, then plummeted by 185.76% to -$1.3 million in 2022, then plummeted by 39.95% to -$1.8 million in 2023, then rose by 25.92% to -$1.3 million in 2024, then soared by 257.46% to $2.1 million in 2025.
  • Business Quant data shows Research & Development for LPCN at $2.1 million in Q3 2025, $3.1 million in Q2 2025, and $109000.0 in Q1 2025.